Immunovant Inc
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 100.0% | – | – | – | 100.0% | – | – | – | – | 100.0% | 100.0% | |
| – | – | 4.3% | – | – | – | 50.0% | – | – | – | – | – | – | |
| – | – | 95.7% | – | – | – | 50.0% | – | – | – | – | 100.0% | – | |
| – | – | 4,403.7% | – | – | – | 58,531.9% | – | – | – | – | 2,010.3% | 7,020.3% | |
| – | – | 988.2% | – | – | – | 12,608.8% | – | – | – | – | 249.4% | 957.2% | |
| – | – | 5,391.9% | – | – | – | 71,140.6% | – | – | – | – | 2,259.7% | 7,977.5% | |
| – | – | -5,391.9% | – | – | – | -71,140.6% | – | – | – | – | -2,159.7% | -7,877.5% | |
| – | – | -5,005.8% | – | – | – | -66,166.3% | – | – | – | – | -2,159.6% | -7,595.7% | |
| – | – | 15.5% | – | – | – | 364.4% | – | – | – | – | – | – | |
| – | – | -5,021.3% | – | – | – | -66,530.6% | – | – | – | – | -2,159.6% | -7,585.9% | |
| – | – | -5,001.5% | – | – | – | -66,098.1% | – | – | – | – | -2,158.3% | -7,590.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.